Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia

Pediatrics

Volumn 130, Issue 5, 2012, Pages

  Sarafoglou, Kyriakie ^a   Banks, Kathryn ^b   Gaviglio, Amy ^b   Hietala, Amy ^b   McCann, Mark ^b   Thomas, William ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MINNESOTA DEPARTMENT OF HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adrenal disorders; False positives negatives; Newborn screening; Population based study

Indexed keywords

ANDROSTENEDIONE; HYDROCORTISONE; HYDROXYPROGESTERONE; SODIUM CHLORIDE; STEROID;

ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRIED BLOOD SPOT TESTING; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FLUOROIMMUNOASSAY; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SCREENING; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; SALT WASTING; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; UNITED STATES; VIRILIZATION;

EID: 84868616867     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-1219     Document Type: Article

References (26)

1. Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977;45(5):1003-1008 (Pubitemid 8238614)
2. Nordenström A, Wedell A, Hagenfeldt L, Marcus C, Larsson A. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics. 2001; 108(4). Available at: www.pediatrics.org/cgi/content/full/108/4/e68
3. Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr. 1997;130(1):128-133 (Pubitemid 27492730)
4. Therrell BL Jr, Berenbaum SA, Manter- Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics. 1998;101(4 pt 1):583-590
5. Thil'en A, Nordenström A, Hagenfeldt L, von Döbeln U, Guthenberg C, Larsson A. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics. 1998;101(4). Available at: www.pediatrics.org/cgi/content/full/101/4/e11
6. Lacey JM, Minutti CZ, Magera MJ, et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem. 2004;50(3):621-625 (Pubitemid 38297314)
7. Wedell A. An update on the molecular genetics of congenital adrenal hyperplasia: diagnostic and therapeutic aspects. J Pediatr Endocrinol Metab. 1998;11(5):581-589 (Pubitemid 28493573)
8. Sarafoglou K, Lorentz CP, Otten N, Oetting WS, Grebe SK. Molecular testing in congenital adrenal hyperplasia due to 21α-hydroxylase deficiency in the era of newborn screening. Clin Genet. 2012;82(1):64-70
9. Gruñeiro-Papendieck L, Prieto L, Chiesa A, Bengolea S, Bossi G, Bergadá C. Neonatal screening program for congenital adrenal hyperplasia: adjustments to the recall protocol. Horm Res. 2001;55(6):271-277 (Pubitemid 34114173)
10. Van der Kamp HJ, Noordam K, Elvers B, Van Baarle M, Otten BJ, Verkerk PH. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics. 2001;108(6):1320-1324 (Pubitemid 33121474)
11. Larson C, Hermos R, Delaney A, Daley D, Mitchell M. Risk factors associated with delayed thyrotropin elevations in congenital hypothyroidism. J Pediatr. 2003;143(5):587-591 (Pubitemid 37452783)
12. Tylek-Lemańska D, Kumorowicz-Kopiec M, Starzyk J. Screening for congenital hypothyroidism: the value of retesting after four weeks in neonates with low and very low birth weight. J Med Screen. 2005;12(4):166-169 (Pubitemid 43843290)
13. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Stat Sci. 2001;16(2):101-133 (Pubitemid 33636344)
14. Gatelais F, Berthelot J, Beringue F, et al. Effect of single and multiple courses of prenatal corticosteroids on 17-hydroxyprogesterone levels: implication for neonatal screening of congenital adrenal hyperplasia. Pediatr Res. 2004;56(5):701-705 (Pubitemid 39403393)
15. Doerr HG, Sippell WG, Versmold HT, Bidlingmaier F, Knorr D. Plasma mineral-ocorticoids, glucocorticoids, and progestins in premature infants: longitudinal study during the first week of life. Pediatr Res. 1988;23(5):525-529
16. Bolt RJ, Van Weissenbruch MM, Popp-Snijders C, Sweep FG, Lafeber HN, Dele-marre- van de Waal HA. Maturity of the adrenal cortex in very preterm infants is related to gestational age. Pediatr Res. 2002;52(3):405-410 (Pubitemid 34920273)
17. Wong T, Shackleton CH, Covey TR, Ellis G. Identification of the steroids in neonatal plasma that interfere with 17 alpha-hydroxyprogesterone radioimmunoassays. Clin Chem. 1992;38(9):1830-1837
18. Varness TS, Allen DB, Hoffman GL. Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls. J Pediatr. 2005;147(4):493-498 (Pubitemid 41446544)
19. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics. 2006;117(6):1915-1921 (Pubitemid 46071234)
20. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA. 2003;290(19):2564-2572 (Pubitemid 37443286)
21. Leslie LK, Boyce WT. Consultation with the specialist. The vulnerable child. Pediatr Rev. 1996;17(9):323-326
22. Schreiner F, Brack C, Salzgeber K, Vorhoff W, Woelfle J, Gohlke B. False negative 17-hydroxyprogesterone screening in children with classical congenital adrenal hyperplasia. Eur J Pediatr. 2008;167(4):479-481 (Pubitemid 351322466)
23. Gudmundsson K, Majzoub JA, Bradwin G, Mandel S, Rifai N. Virilising 21-hydroxylase deficiency: timing of newborn screening and confirmatory tests can be crucial. J Pediatr Endocrinol Metab. 1999;12(6):895-901 (Pubitemid 30002280)
24. Votava F, Török D, Kovács J, et al; Middle European Society for Paediatric Endocrinology - Congenital Adrenal Hyperplasia (MESPE-CAH) Study Group. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2005;152(6):869-874
25. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21(3):245-291 (Pubitemid 32275589)
26. Minutolo C, Nadra AD, Fernández C, et al. Structure-based analysis of five novel disease-causing mutations in 21-hydroxylasedeficient patients. PLoS ONE. 2011;6(1):e15899